Pakistan’s Locally-Prepared Vaccine Gets DRAP Approval

The first locally-packed COVID-19 vaccine, PakVac, has reportedly been approved by the National Biological Control Laboratory (NCLB) of the Pakistan Regulatory Authority of Drugs (DRAP).

PakVac will be officially presented soon in a ceremonial ceremony and will be available for general use by the end of the week, according to sources.

With the support of Chinese healthcare company CanSino Biologics, PakVac is being created at the National Health Institute (NIH). After their raw material reached Pakistan from China last month, NIH started the local manufacture of the vaccine.

At the NIH with the support of Chinese researchers, the first single-dose Pak Vac vaccination with a total of 124,000 doses was created. The following batches will be made by the NIH alone of the CanSinoBIO COVID-19 vaccine.

In collaboration with the Beijing Institute of Biotechnology and in major Phase III clinical studies in five countries, including Pakistan, where over 40,000 volunteers have taken part, the coronavirus vaccine was initially produced by CanSinoBI O also known as Ad5-nCoV.

Study results were released in February of this year, confirming the 65 percent efficacy with CanSinoBIO for symptomatic prevention and 91 percent for serious infection prevention. With respect to the Pakistani subset, the vaccination delivered 75% symptomatic case protection and 100% severity protection.